[1] 郭小兵,田富云,贺小红,等.下呼吸道分离菌106株的分布及耐药性分析[J].郑州大学学报(医学版),2017,52(6):728-732. [2] Chang YT, Lin CY, Chen YH, et al. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanism and therapeutic options[J]. Front Microbiol, 2015,6:893. [3] Smaonis G, Karageorgopoulos DE, Maraki S, et al. Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome[J]. PLoS One, 2012, 7 (5):373-375. [4] Clinical and Laboratory Standards Institute(CLSI). Performance standards for antimicrobial susceptibility testing[S]. CLSI, M100-S25,2017:45-46. [5] 胡付品,朱德妹,汪复,等. 2013年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2014,14(5):365-374. [6] 陈思思,陈韩,陈静超,等.嗜麦芽窄食单胞菌的分布及其药敏分析[J]. 中国卫生检验杂志,2017,27(18):2719-2725. [7] 刘丹.2013-2014年某院嗜麦芽窄食单胞菌临床分布及耐药性分析[J].山东医药,2015,55(1):89-90. [8] 韦志福,郭世辉,梁宏洁.成人ICU与非ICU病区常见细菌分布及耐药性分析[J]. 广西医科大学学报,2017,34(10):1468-1471. [9] Sven J, Susanne S, Birgit W, et al. Widespread dissemination of class 1 integron components in soils and related ecosystems as revealed by cultivation-independent analysis[J]. Front Microbiol, 2013,4:420. [10] Poey ME, Lavina M.Integrons in uropathogenic Escherichia coli and their relationship with phylogeny and virulence[J]. Microb Pathog, 2014,77:73-77. [11] Sun E, Liang G, Wang L, et al. Antimicrobial susceptibility of hospital acquired Stenotrophomonas maltophilia isolate biofilms[J]. Braz J Infect Dis, 2016, 20(4):365-373. [12] Martins N, Picao RC, Adams-Sapper S, et al. Association of class 1 and 2 integrons with multidrug-resistant Acinetobacter baumannii international clones and Acinetobacter nosocomialis isolates[J]. Antimicrob Agents Chemother, 2015, 59(1):698-701. [13] Liaw SJ, Lee YL, Hsueh PR. Multidrug resistance in clinical isolates of Stenotrophomonas maltophilia: roles of integrons, efflux pumps, phosphoglucomutase(SpgM), and melanin and biofilm formation[J]. Int J Antimicrob Agents, 2009, 35(2):126-130.